250 related articles for article (PubMed ID: 21123455)
1. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
[TBL] [Abstract][Full Text] [Related]
2. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F; Hofer E; Wodlej C; Golob-Schwarzl N; Birkl-Toeglhofer AM; Stallinger A; Petzold J; Orlova A; Krassnig S; Reihs R; Niedrist T; Mangge H; Park YN; Thalhammer M; Aigelsreiter A; Lax S; Garbers C; Fickert P; Rose-John S; Moriggl R; Rinner B; Haybaeck J
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):308-321. PubMed ID: 30419338
[TBL] [Abstract][Full Text] [Related]
4. Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.
Ataie-Kachoie P; Morris DL; Pourgholami MH
PLoS One; 2013; 8(4):e60817. PubMed ID: 23593315
[TBL] [Abstract][Full Text] [Related]
5. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
6. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells.
Valle ML; Dworshak J; Sharma A; Ibrahim AS; Al-Shabrawey M; Sharma S
Exp Eye Res; 2019 Jan; 178():27-36. PubMed ID: 30240585
[TBL] [Abstract][Full Text] [Related]
8. Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle.
Ammit AJ; Moir LM; Oliver BG; Hughes JM; Alkhouri H; Ge Q; Burgess JK; Black JL; Roth M
Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L199-206. PubMed ID: 16936245
[TBL] [Abstract][Full Text] [Related]
9. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells.
Syed V; Ulinski G; Mok SC; Ho SM
J Natl Cancer Inst; 2002 Apr; 94(8):617-29. PubMed ID: 11959895
[TBL] [Abstract][Full Text] [Related]
10. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin.
Marin V; Montero-Julian FA; Grès S; Boulay V; Bongrand P; Farnarier C; Kaplanski G
J Immunol; 2001 Sep; 167(6):3435-42. PubMed ID: 11544336
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.
Nakanishi H; Yoshioka K; Joyama S; Araki N; Myoui A; Ishiguro S; Ueda T; Yoshikawa H; Itoh K
Am J Pathol; 2004 Aug; 165(2):471-80. PubMed ID: 15277221
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.
Nilsson MB; Langley RR; Fidler IJ
Cancer Res; 2005 Dec; 65(23):10794-800. PubMed ID: 16322225
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
14. An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthma.
El-Husseini ZW; Khalenkow D; Lan A; van der Molen T; Brightling C; Papi A; Rabe KF; Siddiqui S; Singh D; Kraft M; Beghe B; van den Berge M; van Gosliga D; Nawijn MC; Rose-John S; Koppelman GH; Gosens R
Respir Res; 2023 Dec; 24(1):308. PubMed ID: 38062491
[TBL] [Abstract][Full Text] [Related]
15. Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways.
Pourgholami MH; Ataie-Kachoie P; Badar S; Morris DL
Gynecol Oncol; 2013 Apr; 129(1):113-9. PubMed ID: 23274564
[TBL] [Abstract][Full Text] [Related]
16. SOCS3 limits TNF and endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin-6 signal in human endothelial cells.
Martino N; Bossardi Ramos R; Chuy D; Tomaszek L; Adam AP
Am J Physiol Cell Physiol; 2022 Aug; 323(2):C556-C569. PubMed ID: 35816643
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.
Wang Y; Li L; Guo X; Jin X; Sun W; Zhang X; Xu RC
Cytokine; 2012 Aug; 59(2):228-36. PubMed ID: 22595649
[TBL] [Abstract][Full Text] [Related]
18. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface.
Tang MKS; Yue PYK; Ip PP; Huang RL; Lai HC; Cheung ANY; Tse KY; Ngan HYS; Wong AST
Nat Commun; 2018 Jun; 9(1):2270. PubMed ID: 29891938
[TBL] [Abstract][Full Text] [Related]
19. Soluble IL-6 receptor induces calcium flux and selectively modulates chemokine expression in human dermal fibroblasts.
Spörri B; Müller KM; Wiesmann U; Bickel M
Int Immunol; 1999 Jul; 11(7):1053-8. PubMed ID: 10383937
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 as a therapeutic target in human ovarian cancer.
Coward J; Kulbe H; Chakravarty P; Leader D; Vassileva V; Leinster DA; Thompson R; Schioppa T; Nemeth J; Vermeulen J; Singh N; Avril N; Cummings J; Rexhepaj E; Jirström K; Gallagher WM; Brennan DJ; McNeish IA; Balkwill FR
Clin Cancer Res; 2011 Sep; 17(18):6083-96. PubMed ID: 21795409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
